-
CANNABIDIOL, A FUTURE ANTIBIOTIC?
Read more »Pharmotech owns a patent on CBD and composition thereof as antibacterial compound. This first step was achieved in collaboration with the Geneva University. Our goal is to create different new […]
-
UN health agency lists antibiotic-resistant bacteria which pose human threat
Read more »27 February 2017 – The United Nations health agency today published its first-ever catalogue of antibiotic-resistant bacteria that pose the greatest threat to human health. The list of priority pathogens […]
-
Pseudomonas infections are caused by any of several types of the gram-negative bacteria Pseudomonas, especially Pseudomonas aeruginosa.
Read more »Pseudomonas aeruginosa and other members of this group of gram-negative bacilli are opportunistic pathogens that frequently cause hospital-acquired infections, particularly in ventilator patients, burn patients, and patients with chronic debility. […]
Research & Development
Pharmotech SA focuses its Research and Development (R&D) in the phytopharma world, especially on cannabinoids and on their possible pharmacological applications. We have the best and vastest laboratory just around us: Nature. It is fascinating for us to re-discover its secrets. Switzerland is a country with several positive facets, being one of them its ... to read more click here.
CBD scientific Studies and publications
Dear reader, we hope that this list of publications about cannabinoids and the pharmacological effects of CBD and other cannabinoids, can help you understand the real potential of this new chemical entity. Pharmotech SA is constantly striving to keep its expertise and information up-to-date and will simultaneously inform on this platform our readers on the most important discoveries on the CBD applications. In this subsection we maintain a current list of links on the most important scientific studies on cannabinoids in medicine just click here.